Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography

Posted on
integrative-structural-insights-into-the-igg-fcrn-interactions-revealed-by-engineered-fcrn-immobilized-affinity-chromatography
Integrative structural insights into the IgG-FcRn interactions revealed by engineered FcRn-immobilized affinity chromatography

References

  1. Crescioli, S. et al. Antibodies to watch in 2024. mAbs 16, 2297450 (2024).

    Google Scholar 

  2. Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the ‘high-hanging fruit. Nat. Rev. Drug Discov. 17, 197–223 (2018).

    Google Scholar 

  3. Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641–661 (2023).

    Google Scholar 

  4. Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585–608 (2019).

    Google Scholar 

  5. Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22, 868–876 (2011).

    Google Scholar 

  6. Keizer, R. J., Huitema, A. D., Schellens, J. H. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. pharmacokinet. 49, 493–507 (2010).

    Google Scholar 

  7. Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H. & Chetty, M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin. pharmacokinet. 52, 83–124 (2013).

    Google Scholar 

  8. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715–725 (2007).

    Google Scholar 

  9. Bussel, J. B., Cines, D. B. & Blumberg, R. S. Neonatal Fc receptor—biology and therapeutics. N. Engl. J. Med. 392, 1621–1635 (2025).

    Google Scholar 

  10. Borrok, M. J. et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J. Biol. Chem. 290, 4282–4290 (2015).

    Google Scholar 

  11. Grevys, A. et al. Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. iScience 25, 103746 (2022).

    Google Scholar 

  12. Datta-Mannan, A. et al. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs 7, 483–493 (2015).

    Google Scholar 

  13. Chirmule, N., Jawa, V. & Meibohm, B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 14, 296–302 (2012).

    Google Scholar 

  14. Opolka-Hoffmann, E. et al. The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance. mAbs 13, 1995929 (2021).

    Google Scholar 

  15. Reusch, J., Andersen, J. T., Rant, U. & Schlothauer, T. Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn. mAbs 16, 2361585 (2024).

    Google Scholar 

  16. Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L. & Bjorkman, P. J. Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 372, 336–343 (1994).

    Google Scholar 

  17. Burmeister, W. P., Huber, A. H. & Bjorkman, P. J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372, 379–383 (1994).

    Google Scholar 

  18. West, A. P. Jr & Bjorkman, P. J. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 39, 9698–9708 (2000).

    Google Scholar 

  19. Martin, W. L., West, A. P. Jr, Gan, L. & Bjorkman, P. J. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7, 867–877 (2001).

    Google Scholar 

  20. Jensen, P. F. et al. A Two-pronged binding mechanism of IgG to the neonatal Fc receptor controls complex stability and IgG serum half-life. Mol. Cell. Proteom. MCP 16, 451–456 (2017).

    Google Scholar 

  21. Gjolberg, T. T. et al. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun. Biol. 5, 832 (2022).

    Google Scholar 

  22. Trabjerg, E. et al. Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation. Commun. Biol. 8, 922 (2025).

    Google Scholar 

  23. Booth, B. J. et al. Extending human IgG half-life using structure-guided design. mAbs 10, 1098–1110 (2018).

    Google Scholar 

  24. Pyzik, M. et al. The neonatal Fc receptor (FcRn): a misnomer? Front. Immunol. 10, 1540 (2019).

    Google Scholar 

  25. Suzuki, T. et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184, 1968–1976 (2010).

    Google Scholar 

  26. Brinkhaus, M. et al. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement. Nat. Commun. 13, 6073 (2022).

    Google Scholar 

  27. Liu, S., Verma, A., Kettenberger, H., Richter, W. F. & Shah, D. K. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. mAbs 13, 1993769 (2021).

    Google Scholar 

  28. Rossini, S. et al. V region of IgG controls the molecular properties of the binding site for neonatal FC receptor. J. Immunol. 205, 2850–2860 (2020).

    Google Scholar 

  29. Ollier, R. et al. Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework. mAbs 15, 2232087 (2023).

    Google Scholar 

  30. Piche-Nicholas, N. M. et al. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. mAbs 10, 81–94 (2018).

    Google Scholar 

  31. Schoch, A. et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc. Natl. Acad. Sci. USA 112, 5997–6002 (2015).

    Google Scholar 

  32. Schlothauer, T. et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs 5, 576–586 (2013).

    Google Scholar 

  33. Stracke, J. et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs 6, 1229–1242 (2014).

    Google Scholar 

  34. Abdiche, Y. N. et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. mAbs 7, 331–343 (2015).

    Google Scholar 

  35. Igawa, T. et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng. Des. Sel. PEDS 23, 385–392 (2010).

    Google Scholar 

  36. Cymer, F., Schlothauer, T., Knaupp, A. & Beck, H. Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants. Bioanalysis 9, 1305–1317 (2017).

    Google Scholar 

  37. Grevys, A. et al. A human endothelial cell-based recycling assay for screening of FcRn targeted molecules. Nat. Commun. 9, 621 (2018).

    Google Scholar 

  38. Suzuki, T., Hashii, N., Tada, M. & Ishii-Watabe, A. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: analysis of FcRn-binding engineered antibodies and an Fc fusion protein. mAbs 13, 1923366 (2021).

    Google Scholar 

  39. Schmidt, M. M. et al. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Structure 21, 1966–1978 (2013).

    Google Scholar 

  40. Boswell, C. A. et al. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chem. 21, 2153–2163 (2010).

    Google Scholar 

  41. Khawli, L. A. et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2, 613–624 (2010).

    Google Scholar 

  42. Gan, Z., Ram, S., Vaccaro, C., Ober, R. J. & Ward, E. S. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10, 600–614 (2009).

    Google Scholar 

  43. He, W. et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 455, 542–546 (2008).

    Google Scholar 

  44. Sun, Y., Estevez, A., Schlothauer, T. & Wecksler, A. T. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. mAbs 12, 1802135 (2020).

    Google Scholar 

  45. Asaoka, Y., Hatayama, K., Tsumoto, K., Tomita, M. & Ide, T. Engineering of recombinant human Fcgamma receptor I by directed evolution. Protein Eng. Des. Sel. PEDS 25, 835–842 (2012).

    Google Scholar 

  46. Bertolotti-Ciarlet, A. et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol. Immunol. 46, 1878–1882 (2009).

    Google Scholar 

  47. Liu, H., Gaza-Bulseco, G., Xiang, T. & Chumsae, C. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol. Immunol. 45, 701–708 (2008).

    Google Scholar 

  48. Liu, D. et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 47, 5088–5100 (2008).

    Google Scholar 

  49. Datta-Mannan, A. et al. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos. Biol. Fate Chem. 35, 86–94 (2007).

    Google Scholar 

  50. Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157–159 (2010).

    Google Scholar 

  51. Deng, R. et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab. dispos. Biol. Fate Chem. 38, 600–605 (2010).

    Google Scholar 

  52. Yeung, Y. A. et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 70, 3269–3277 (2010).

    Google Scholar 

  53. Hinton, P. R. et al. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213–6216 (2004).

    Google Scholar 

  54. Dall’Acqua, W. F. et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169, 5171–5180 (2002).

    Google Scholar 

  55. Kim, J. K. et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29, 2819–2825 (1999).

    Google Scholar 

  56. Gasteiger, E. et al. Protein identification and analysis tools on the ExPASy server. The Proteomics Protocols Handbook. https://doi.org/10.1385/1-59259-890-0:571 (2005).

Download references

Related Posts